Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06904482 · ClinicalTrials.gov registry record · Phase 2
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
A Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06904482: Recruiting Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Case Comprehensive Cancer Center.
NCT06904482 is a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 36 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06904482, a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Primary Outcome
Kaplan-Meier method will be used to estimate the PFS
Conditions Studied
Interventions
- BIOLOGICAL Haplo-Identical / Cord Blood Transplant
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2030-02-25 |
| Phase | Phase 2 |
What NCT06904482 shows while recruiting
NCT06904482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower).
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Haplo-Identical / Cord Blood Transplant is the first listed.
NCT06904482 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06904482 about?
NCT06904482 is a clinical study titled "Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood". The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
What is the current status of trial NCT06904482?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2025-08-13. Estimated completion is 2030-02-25.
What conditions does trial NCT06904482 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, aGVHD.
What interventions are being tested in trial NCT06904482?
The interventions under investigation include: Haplo-Identical / Cord Blood Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06904482?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06904482 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06904482's enrollment target sits among peer trials
36 110th of 173 higher than 62 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI